PP34 Cost Utility Of Lenalidomide With Rituximab For Follicular Lymphoma In Previously Treated Patients: The Brazilian Healthcare System Perspective
Ludmila Gargano, Layssa Oliveira, Haliton Oliveira Junior, Rosa Camila Lucchetta · 2025
Read PP34 Cost Utility Of Lenalidomide With Rituximab For Follicular Lymphoma In Previously Treated Patients: The Brazilian Healthcare System Perspective by Ludmila Gargano, Layssa Oliveira, Haliton Oliveira Junior, Rosa Camila Lucchetta (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768811.txt.
Description
Ludmila Gargano and three co-authors weigh the cost utility of a drug pair for follicular lymphoma in Brazil in this 2025 paper. The pair joins lenalidomide with rituximab for patients whose cancer returned after first treatment. Brazil's public system now leans on rituximab with chemotherapy for such cases. The team built a survival model from a clinical trial, stretched over forty years, and priced drugs and care across the course.
The pair added about three quality adjusted life years per patient, at a high added cost. The cost per added year still fell below Brazil's stated threshold, so the pair counted as cost effective. Listing the pair would raise the public budget by about twelve and a half million dollars over five years at a fifty percent share. The authors conclude the pair could serve relapsed patients better than standard care, within the system's limits.
Catalog record
| CREATOR | Ludmila Gargano, Layssa Oliveira, Haliton Oliveira Junior, Rosa Camila Lucchetta |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |